Novartis AG - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
NVS New York 2834 www.novartis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Novartis AG

INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Mar 9th, 2026 10:11 am
Novartis Advances Immunology And Oncology Plans As Valuation Gap Persists - Mar 6th, 2026 11:06 pm
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting - Mar 6th, 2026 6:24 am
Novartis, Nucor partner US Forged Rings and others expand domestic investments - Mar 6th, 2026 3:55 am
Paroxysmal Nocturnal Hemoglobinuria Market Enters Transition Phase as Second-Line Opportunities Expand Amid Ongoing Barriers to Adoption of Newer Agents, According to Spherix Global Insights - Mar 5th, 2026 8:14 am
What This Top International ETF Is Buying Now - Mar 4th, 2026 12:00 am
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU - Mar 3rd, 2026 8:50 am
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now - Mar 3rd, 2026 7:50 am
7MM Asthma Market Insights, Epidemiology, and Market Forecast Report 2022-2036 - Mar 3rd, 2026 7:40 am
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study - Mar 3rd, 2026 7:20 am
Botanical and Plant-derived Drugs Global Research Report 2025: A $58.1 Billion Market by 2030, Driven by Plant Metabolites for Drug Discovery and Biotechnological Integration for Personalized Medicine - Mar 3rd, 2026 7:12 am
AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0 - Mar 3rd, 2026 2:24 am
As Investors Flee U.S. Equities, This Global ETF Is Outperforming - Mar 2nd, 2026 6:23 am
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Mar 2nd, 2026 2:05 am
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory - Feb 28th, 2026 8:07 am
Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas - Feb 28th, 2026 12:21 am
Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger - Feb 27th, 2026 2:05 pm
Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug - Feb 27th, 2026 2:04 pm
Sector Update: Health Care Stocks Advance Late Afternoon - Feb 27th, 2026 2:02 pm
Sector Update: Health Care Stocks Higher Friday Afternoon - Feb 27th, 2026 12:01 pm